Related Experiment Video

Updated: Jan 28, 2026

Author Spotlight: Workflow for Integrating POCUS Data into EHR for Managing Heart Failure Patients
03:47

Author Spotlight: Workflow for Integrating POCUS Data into EHR for Managing Heart Failure Patients

Published on: July 12, 2024

1.1K

Sacubitril/Valsartan in Real-Life Practice: Experience in Patients with Advanced Heart Failure and Systematic Review

Carles Moliner-Abós1, Mercedes Rivas-Lasarte1, Julia Pamies Besora1

  • 1Cardiology Department, Hospital de la Santa Creu i Sant Pau, IIB-SantPau, CIBERCV, Universidad Autónoma de Barcelona, Calle Sant Antoni Maria Claret 167, 08025, Barcelona, Spain.

Cardiovascular Drugs and Therapy
|March 2, 2019
PubMed

Insights

Sacubitril/valsartan effectively reduced heart failure hospitalizations and improved cardiac function in advanced heart failure patients in real-world practice. The medication demonstrated a good safety profile, with no severe adverse events observed during the follow-up period.

Area of Science:

  • Cardiology
  • Pharmacology
  • Clinical Trials

Background:

  • Sacubitril/valsartan demonstrated efficacy in the PARADIGM-HF trial for heart failure (HF) admissions and cardiovascular mortality.
  • Real-world data comparing daily practice patients with trial participants are limited.

Purpose of the Study:

  • To analyze the efficacy and safety of sacubitril/valsartan in an advanced heart failure cohort.
  • To systematically review previous real-life studies on sacubitril/valsartan.

Main Methods:

  • Retrospective analysis of 108 patients prescribed sacubitril/valsartan in a tertiary HF clinic (Sept 2016 - Feb 2018).
  • Assessed HF admissions before and after drug initiation.
  • Conducted a systematic review of published real-life studies.

Main Results:

  • Patients were in a more advanced NYHA class than in PARADIGM-HF.
  • Observed significant reduction in HF hospitalizations, NT-proBNP levels, and need for levosimendan.
  • Found significant improvement in LVEF and left ventricle diameter.
  • Sacubitril/valsartan was well-tolerated with no severe adverse effects.

Conclusions:

  • Sacubitril/valsartan is prescribed to advanced HF populations in real-world settings.
  • Despite challenges in achieving high doses, the drug significantly reduces HF hospitalizations and improves cardiac reverse remodeling.
  • Demonstrated a favorable safety profile in this advanced HF cohort.
Abstract

Keywords:
Heart failureReal-life practiceReviewSacubitril/valsartan

More Related Videos

Integration of Brain Tissue Saturation Monitoring in Cardiopulmonary Exercise Testing in Patients with Heart Failure04:20

Integration of Brain Tissue Saturation Monitoring in Cardiopulmonary Exercise Testing in Patients with Heart Failure

Published on: October 1, 2019

6.2K
Author Spotlight: Unveiling Prognostic Indicators in Heart Failure - The Role of Phase Angle and Bioelectrical Impedance Analysis04:05

Author Spotlight: Unveiling Prognostic Indicators in Heart Failure - The Role of Phase Angle and Bioelectrical Impedance Analysis

Published on: June 30, 2023

2.8K

Related Concept Videos

Pathophysiology of Heart Failure01:17

Pathophysiology of Heart Failure

Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
3.5K
Heart Failure I: Introduction01:27

Heart Failure I: Introduction

Heart failure refers to a clinical syndrome caused by structural or functional cardiac disorders that prevent the heart from pumping an adequate amount of blood to meet the body's metabolic needs. This condition often arises from myocardial infarction or ischemia, leading to decreased cardiac output, reduced tissue perfusion, impaired gas exchange, fluid volume imbalance, and decreased functional ability.Heart failure can result from disruptions in the mechanisms that regulate cardiac output...
847
Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
872
Heart Failure Drugs: Diuretics01:22

Heart Failure Drugs: Diuretics

Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
948
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
272
Heart Failure VI: Adjunct Therapies01:22

Heart Failure VI: Adjunct Therapies

Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
314